Related Experiment Videos
Orbital rhabdomyosarcoma
Zeynel A Karcioglu1, Doris Hadjistilianou, Marta Rozans
1Department of Ophthalmology and Cancer Center, Tulane University Health Sciences Center, New Orleans, LA 70112, USA. zkarcio@tulane.edu
Cancer Control : Journal of the Moffitt Cancer Center
|September 21, 2004
Summary
Orbital rhabdomyosarcoma (RMS) is a common challenge for ocular oncologists. Advances in chemotherapy and radiotherapy have improved survival rates for this rare orbital tumor.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Medical Imaging
Background:
- Rhabdomyosarcoma (RMS) is a rare mesenchymal malignancy but a significant diagnostic and management challenge in ocular oncology.
- Orbital RMS presents a unique set of challenges for clinicians managing pediatric orbital tumors.
Purpose of the Study:
- To review the diagnosis and management of orbital rhabdomyosarcoma.
- To highlight key imaging findings and treatment strategies for orbital RMS.
- To discuss long-term complications and challenges associated with improved survival.
Main Methods:
- A comprehensive literature search was performed using PubMed.
- Articles published over the last 30 years were reviewed.
Main Results:
- Orbital RMS typically appears as a space-occupying lesion in the first decade of life, often in the superior nasal quadrant.
- Clinical presentation varies with tumor location and growth rate; embryonal and alveolar types are most common.
- CT and MRI are crucial for evaluating bone invasion and intracranial/paranasal sinus extension. Treatment involves chemotherapy, radiation, and surgical biopsy.
Conclusions:
- Improved survival for orbital RMS is attributed to advances in chemotherapy and radiotherapy.
- Long-term survivors face increased risks of post-treatment complications, including radiotherapy side effects, secondary malignancies, and visual dysfunction.
- Managing these long-term complications presents new challenges in the care of orbital rhabdomyosarcoma patients.